GlassScriptPhysician profile
John R Oglesbee
NPI 1851485361
$1,242.83
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,095 · 2020: $147.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $428.54 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.81 | 2019-2020 | |
| Abbott Laboratories | $94.70 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $80.75 | 2019 | |
| Novo Nordisk INC | $79.01 | 2019 | |
| Glaxosmithkline, LLC. | $64.89 | 2019-2020 | |
| Amgen INC. | $56.40 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $50.58 | 2019 | |
| Allergan, INC. | $33.07 | 2019 | |
| Sanofi-Aventis U.S. LLC | $32.09 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.21 | 2019 | |
| Grifols USA, LLC | $30.08 | 2019 | |
| Lilly USA, LLC | $28.36 | 2020 | |
| Edwards Lifesciences Corporation | $18.84 | 2019 | |
| Sanofi Pasteur INC. | $17.23 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $14.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.11 | 2019 | |
| Radius Health, INC. | $11.83 | 2019 | |
| Pfizer INC. | $11.28 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Oglesbee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.